drugset / Trial / NCT05849766
Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction
Phase 3
Completed
150 enrolled
October 6 University
National Heart Institute, Egypt · collabUniversity of Florida · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A significant reduction in the incidence of CV death or hospitalization for HF has been observed in randomized trials investigating the CV benefit of Dapagliflozin. Mechanistic investigations are required to interpret the positive clinical effects of Dapagliflozin on heart structure and valvular regurgitation.
Timeline
- Start
- 2023-04-27
- Primary completion
- 2024-05-01
- Completion
- 2024-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapagliflozin | Small molecule | 10 mg | — |
| Comparator | Carvedilol | Other / unclassified | 6.25 mg | — |
| Comparator | Ramipril | Small molecule | 10 mg | — |
| Comparator | Spironolactone | Small molecule | 25 mg | — |